Your browser doesn't support javascript.
loading
Estimating direct costs of the treatment for mucosal leishmaniasis in Brazil
Carvalho, Janaína de Pina; Assis, Tália Machado de; Simões, Taynãna César; Cota, Gláucia.
  • Carvalho, Janaína de Pina; Fundação Oswaldo Cruz. Instituto René Rachou. Grupo de Pesquisa Clínica e Políticas Públicas em Doenças Infecciosas e Parasitárias. Belo Horizonte. BR
  • Assis, Tália Machado de; Fundação Oswaldo Cruz. Instituto René Rachou. Grupo de Pesquisa Clínica e Políticas Públicas em Doenças Infecciosas e Parasitárias. Belo Horizonte. BR
  • Simões, Taynãna César; Fundação Oswaldo Cruz. Instituto René Rachou. Grupo de Pesquisa Clínica e Políticas Públicas em Doenças Infecciosas e Parasitárias. Belo Horizonte. BR
  • Cota, Gláucia; Fundação Oswaldo Cruz. Instituto René Rachou. Grupo de Pesquisa Clínica e Políticas Públicas em Doenças Infecciosas e Parasitárias. Belo Horizonte. BR
Rev. Soc. Bras. Med. Trop ; 54: e04542020, 2021. tab
Article Dans Anglais | LILACS | ID: biblio-1155531
ABSTRACT
Abstract

INTRODUCTION:

The objective of this study was to estimate the direct medical costs of the treatment for mucosal leishmaniasis (ML) using three therapeutic approaches in the Brazilian context.

METHODS:

We performed this economic assessment from the perspective of the Brazilian public healthcare system. The following therapeutic approaches were evaluated meglumine antimoniate, liposomal amphotericin B, and miltefosine. Direct medical costs were estimated considering four treatment components a) drug, b) combined medical products, c) procedures, and d) complementary tests.

RESULTS:

Treatment with meglumine antimoniate had the lowest average cost per patient (US$ 167.66), followed by miltefosine (US$ 259.92) in the outpatient treatment regimen. The average cost of treatment with liposomal amphotericin B was US$ 715.35 both in inpatient regimen. In all estimates, the drugs accounted for more than 60% of the total cost for each treatment approach.

CONCLUSIONS:

These results demonstrate the marked differences in costs between the therapeutic alternatives for ML. In addition to efficacy rates and costs related to adverse events, our data have the potential to support a complete cost-effectiveness study in the future. Complete analyses comparing costs and benefits for interventions will assist health managers in choosing drugs for ML treatment in Brazil as well as in establishing effective public health policies.
Sujets)


Texte intégral: Disponible Indice: LILAS (Amériques) Sujet Principal: Leishmaniose cutanéomuqueuse / Antiprotozoaires Type d'étude: Évaluation en économique de la santé Limites du sujet: Humains Pays comme sujet: Amérique du Sud / Brésil langue: Anglais Texte intégral: Rev. Soc. Bras. Med. Trop Thème du journal: Médecine tropicale Année: 2021 Type: Article Pays d'affiliation: Brésil Institution/Pays d'affiliation: Fundação Oswaldo Cruz/BR

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS


Texte intégral: Disponible Indice: LILAS (Amériques) Sujet Principal: Leishmaniose cutanéomuqueuse / Antiprotozoaires Type d'étude: Évaluation en économique de la santé Limites du sujet: Humains Pays comme sujet: Amérique du Sud / Brésil langue: Anglais Texte intégral: Rev. Soc. Bras. Med. Trop Thème du journal: Médecine tropicale Année: 2021 Type: Article Pays d'affiliation: Brésil Institution/Pays d'affiliation: Fundação Oswaldo Cruz/BR